The abstract and presentation above represent data to be exhibited or made public by Gan & Lee. This press release contains forward-looking statements regarding investigational drugs currently in development by Gan & Lee. It is important to remember that drug development involves risks and there can be no guarantee that future studies will produce results consistent with those presented at the ADA 84th Scientific Session.
references:
[1]ADA 84Number Scientific Sessions. https://professional.diabetes.org/scientific-sessions
[2]Zhang M, Zhang Y, Peng X, et al. GZR18, a novel long-acting GLP-1 analogue, exhibited favorable pharmacokinetic and pharmacodynamic properties in vitro and in vivo in animal models. Eur J Pharmacol. 2022;928:175107. doi:10.1016/j.ejphar.2022.175107
About Gan & Lee
Gan Li Pharmaceutical developed China’s first domestic insulin analogue. Currently, Gan Li has six main insulin products, five of which are long-acting insulin glargine injections (Basaline).®), immediate-release lispro injection (Prandilin™), Rapid-acting Aspart Injection (Lapirin®), Mixed Protamine Zinc Lispro Injection (25R) (Prandiline™25), Aspart 30 Injection (Lapirin®30), and one bottle of human insulin injection – Mixed Protamine Human Insulin Injection (30R) (Similin®30) The company has two approved medical devices. ChinaReusable insulin injection pen (GanleePen) and disposable pen-type needle (GanleeFine)®).
in Chinese 2nd Quantity-Based Procurement (Gan & Lee Pharmaceutical ranked second among domestic companies and first overall in the procurement demand for insulin analogues in 2024. The company also has a strong track record in the procurement of disposable pen-type injection needles (Ganley Fine®) Approved by the U.S. Food and Drug Administration (FDA) in 2020, In 2020, it received GMP inspection approval from the European Medicines Agency (EMA).24. These achievements have significantly improved Gan & Lee’s competitiveness in both the international and domestic markets.
Going forward, Gan & Lee will pursue its mission of becoming a world-class pharmaceutical company with comprehensive coverage of diabetes treatment, focus on the treatment of metabolic diseases, cardiovascular diseases and other therapeutic areas, and actively engage in the development of new chemical entities and biological medicines.
Further information
[email protected](media)
[email protected](Business Development)
SOURCE Gan & Lee Pharmaceuticals
